Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Hepatic Impairment)

In this article, we will discuss Olaparib (Hepatic Impairment). So, let’s get started.

Hepatic Impairment
No adjustment to the starting dose is required in patients with mild hepatic impairment. A 15% increase in mean exposure (AUC) was observed in patients with mild hepatic impairment (based on Child-Pugh classification A) compared to patients with normal hepatic function. There are no data in patients with moderate or severe hepatic impairment.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.